Researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). They’ve developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth.
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024Metronidazole for bacterial infection
February 1, 2023